Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.

Item
http://www.wikidata.org/entity/Q43042527
Successful natural interferon-β plus ribavirin therapy in a chronic hepatitis C patient after discontinuation of interferon-α treatment due to arrhythmia and interstitial pneumonia.Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo studyInfluence of insulin resistance on the development of hepatocellular carcinoma after antiviral treatment for non-cirrhotic patients with chronic hepatitis C.Serotonin and its implication in the side-effects of interferon-based treatment of patients with chronic viral hepatitis: Pharmacological interventions.De novo membrano-proliferative nephritis following interferon therapy for chronic hepatitis C (case study and literature review).Hepatitis C in HIV-infected patients: impact of direct-acting antivirals.NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b.Correlation between polymorphism in the inosine triphosphatase and the reductions in hemoglobin concentration and ribavirin dose during sofosbuvir and ribavirin therapy.Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75 years and over with or without cirrhosis.Prevalence and detection of neuropsychiatric adverse effects during hepatitis C treatment.Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.Comparative safety study on severe anemia by simeprevir versus telaprevir-based triple therapy for chronic hepatitis C.Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.Diabetes Mellitus Prevents an Improvement in the Serum Albumin Level During Interferon-free Sofosbuvir-based Therapy for Chronic Hepatitis C Patients: A Multi-institutional Joint Study.
P2860

Evaluation of the adverse effect of premature discontinuation of pegylated interferon α-2b and ribavirin treatment for chronic hepatitis C virus infection: results from Kyushu University Liver Disease Study.

Item
http://www.wikidata.org/entity/Q43042527
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Evaluation of the adverse effe ...... niversity Liver Disease Study.
@en
Evaluation of the adverse effe ...... niversity Liver Disease Study.
@nl
type
label
Evaluation of the adverse effe ...... niversity Liver Disease Study.
@en
Evaluation of the adverse effe ...... niversity Liver Disease Study.
@nl
prefLabel
Evaluation of the adverse effe ...... niversity Liver Disease Study.
@en
Evaluation of the adverse effe ...... niversity Liver Disease Study.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P577
P698
P356
P1433
P1476
Evaluation of the adverse effe ...... niversity Liver Disease Study.
@en
P2093
P2860
P304
P31
P356
10.1111/J.1440-1746.2011.06965.X
P433
P478
P577
P698